Meeting
2015 Gastrointestinal Cancers Symposium
PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer—A GERCOR Study.
Authors
Benoist Chibaudel
Institut Hospitalier Franco-Britannique, Levallois-Perret, France
Benoist Chibaudel , Frederique Maindrault-Goebel , Thierry André , Jean Baptiste Bachet , Christophe Louvet , Ahmed Khalil Sr., Olivier Jean Marie Dupuis , Pascal Hammel , Marie Line Garcia , Mostefa Bennamoun , David Brusquant , Claire Arbaud , Yi-Wen Wang , Grace Yeh , Franck Bonnetain , Aimery De Gramont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01375816
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 751)
DOI
10.1200/jco.2015.33.3_suppl.751
Abstract #
751
Poster Bd #
E41
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.
First Author: Michael J. Overman
Poster
2021 Gastrointestinal Cancers Symposium
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).
First Author: Andrew L. Coveler
First Author: Valerie Boige
Poster
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
First Author: Masato Nakamura